Enasidenib (AG-221) on the other hand is currently used in clinical settings to treat AML patients with IDH2 mutations, administered with ARAC+DAU combinations during induction or consolidation27, or with AZC28. This evidence concerns the gene IDH2 and acute myeloid leukemia.